Arrowstreet Capital’s Travere Therapeutics TVTX Stock Holding History

Arrowstreet Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.13M	Buy	+55,037	New	+$2.44M	﹤0.01%	1425
2026 Q1	–	Sell	-268,045	Closed	-$10.2M	–	2099
2025 Q4	$10.2M	Sell	268,045 -60,609	-18%	-$1.97M	0.01%	920
2025 Q3	$7.85M	Buy	+328,654	New	+$6.18M	0.01%	1029
2020 Q3	–	Sell	-197,552	Closed	-$4.03M	–	2525
2020 Q2	$4.03M	Buy	+197,552	New	+$3.15M	0.01%	1145
2018 Q2	–	Sell	-110,714	Closed	-$2.48M	–	1306
2018 Q1	$2.48M	Buy	110,714 +76,700	+225%	+$1.83M	0.01%	712
2017 Q4	$717K	Buy	34,014 +22,114	+186%	+$505K	﹤0.01%	1015
2017 Q3	$296K	Buy	+11,900	New	+$262K	﹤0.01%	1006

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's TVTX Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 55,037 shares worth $3.13M. The stake represents ﹤0.01% of the portfolio and ranks #1425 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in TVTX as recently as Q4 2025.

Arrowstreet Capital first reported a position in TVTX in Q3 2017 and has held it in 7 quarters since. The position peaked at $10.2M in Q4 2025. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Arrowstreet Capital held 55,037 shares of Travere Therapeutics worth $3.13M as of Q2 2026.
Travere Therapeutics was a new Arrowstreet Capital position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1425 holding.
Arrowstreet Capital first reported a position in Travere Therapeutics in Q3 2017 and has held it in 7 quarters since.
Arrowstreet Capital's Travere Therapeutics position peaked at $10.2M in Q4 2025.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.